At a glance
A modified IGF-1 analogue used to explore growth-factor signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses cell growth and metabolic effects. Biomarker or animal findings do not establish a safe performance-enhancement protocol.
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of IGF-1 LR3.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 1 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~0.333 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg (0.02 mg) | 6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (0.04 mg) | 12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (0.05 mg) | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose[3]. This schedule uses the maximum practical dilution (3.0 mL) for clear measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily subcutaneous regimen.
- Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability[1].
- Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods.
- Dose Range: 20–50 mcg daily with gradual titration; conservative protocols remain at ≤50 mcg/day.
- Reconstitution: 3.0 mL per 1 mg vial (~0.333 mg/mL or 333 mcg/mL) for precise unit measurements.
- Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles.
- Cycling: Common approach is 8 weeks on, 4–8 weeks off to prevent receptor desensitization[7].
Suggested daily titration approach for tolerance assessment.
- Start (Weeks 1–2): 20 mcg daily to assess tolerance, particularly regarding blood glucose effects[6].
- Titrate (Weeks 3–4): Increase to 40 mcg daily if Week 1–2 well-tolerated with no significant hypoglycemic symptoms.
- Maintain (Weeks 5–8): Hold at 50 mcg daily; this is considered the conservative upper end for most research protocols[2].
- Frequency: Once per day subcutaneously; timing often aligned with meals (morning or post-workout) to manage insulin-like effects.
- Cycle Length: 8 weeks is standard; 12-week protocols exist but may show diminished returns beyond Week 6–8[7].
- Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent local irritation or lipohypertrophy[8].
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not shake.
- Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
- Label the vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at −20 °C (−4 °F) for up to 3–6 months[4].
Storage Instructions
Proper storage is critical to maintain peptide stability and potency.
- Lyophilized (unopened): Store at −20 °C (−4 °F) or colder (−80 °C optimal) in dry, dark conditions for up to 12 months[4]; short-term storage at 2–8 °C (35.6–46.4 °F) for several months is acceptable.
- Reconstituted solution: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 30 days for optimal potency[9].
- Extended storage of reconstituted solution: For storage beyond 30 days, prepare sterile aliquots and freeze at −20 °C (−4 °F); aliquots remain stable for 3–6 months[4]. Never refreeze a thawed vial.
- Handling: Allow frozen vials to reach room temperature before opening to minimize condensation; always inspect solution for clarity (discard if cloudy or contains particles)[10].
- Protection: Keep all vials protected from light and maintain cold chain during storage.
Injection Technique
Subcutaneous injection guidance based on clinical best practices[13][13].
Materials & quantity planning
Source materials checklist · 1 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (IGF-1 LR3, 1 mg each):
- 8 weeks ≈ 3 vials (~2.24 mg total needed)
- 12 weeks ≈ 4 vials (~3.64 mg total needed)
- 16 weeks ≈ 6 vials (~5.04 mg total needed)
-
Insulin Syringes (U-100, 0.5 mL or 1 mL):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
- Sharps Container: For safe disposal of used needles and syringes[5].
- Fast-acting carbohydrate source: Glucose tablets or juice on hand during cycle to address potential hypoglycemia symptoms, especially during dose titration[6].
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 1 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 13
Public health resource
NCBI Bookshelf — 5.6 Administering Subcutaneous Medications: Clinical best practices for subcutaneous injection technique (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.